|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1989-3-16
|
|
pubmed:abstractText |
The evolution of in vitro bone marrow clonogenic leukaemic cells (CFU-L) drug sensitivity was studied in 23 patients with acute myeloid leukaemia treated with anthracycline and cytosine arbinoside (ara-C). In 12 patients tested before and after first induction treatment failure (interval: 6 +/- 4 weeks), the sensitivity remained stable for daunorubicin and showed little variation for ara-C. Among eleven patients tested before treatment and at first relapse (interval: 13 +/- 7 months), in vitro CFU-L sensitivity revealed no correlation between the two measurements, and a trend in decreased sensitivity to daunorubicin and ara-C. These findings suggest that induction failures could be related to factors other than simple selection of a resistant CFU-L subclone.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-286608,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-2946333,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-2963271,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-312670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-3478535,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-3589695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-3857945,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6223674,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6580036,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6590097,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6692253,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6931620,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6939952,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6940626,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6949614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3219266-6961270
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
570-4
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:3219266-Adult,
pubmed-meshheading:3219266-Aged,
pubmed-meshheading:3219266-Antibiotics, Antineoplastic,
pubmed-meshheading:3219266-Clone Cells,
pubmed-meshheading:3219266-Cytarabine,
pubmed-meshheading:3219266-Daunorubicin,
pubmed-meshheading:3219266-Drug Screening Assays, Antitumor,
pubmed-meshheading:3219266-Humans,
pubmed-meshheading:3219266-Leukemia, Myeloid, Acute,
pubmed-meshheading:3219266-Middle Aged
|
|
pubmed:year |
1988
|
|
pubmed:articleTitle |
In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
|
|
pubmed:affiliation |
Service d'Hèmatologie de l'Hôtel-Dieu, Paris.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
